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Summary
Background: The domains of pain, function and patient’s global assessment are identified as core variables and frequently measured in
clinical trials of patients with osteoarthritis (OA) of the hip and knee.
Objective: To develop response criteria for OA of hip and knee based on the domains of pain, function and patient’s global assessment.
Methods: A methodology was developed by an interaction of the Osteoarthritis Research Society International Standing Committee on
Clinical Trials, biostatisticians, pharmaceutical company representatives and health agency representatives. Data from previously conducted
placebo-controlled clinical trials were normalized and collated. Data were subset by location of OA (knee, hip), active agent used in the
clinical trial (non-steroidal anti-inflammatory drug, other agent) and route of administration (oral, intra-articular). Statistical analysis identified
response criteria which best discriminate active agent from placebo.
Results: Based on the analysis of data from 14 studies (totaling 1886 patients) and consensus opinion, the optimal responder criteria set
differed for location of OA, active agent to be used, and route of administration. Because of nearly identical statistical results, two sets of
responder criteria are proposed: (1) ‘high’ pain response or, alternatively, a ‘moderate’ response for at least two of three domains: pain,
function and patient’s global assessment; (2) ‘high’ response for either pain or function or, alternatively, a ‘moderate’ response for at least
two of three domains: pain, function and patient’s global assessment. The sensitivity (i.e., the percentage of responders in the active group)
ranged from 52 to 96% and the specificity (i.e., the percentage of nonresponders in the control group) from 47 to 73%.
Conclusion: Based on data from clinical trials, two sets of responder criteria have been developed that can categorize an individual’s
responses to treatment in a clinical trial. These responder criteria require validation in additional datasets. © 2000 OsteoArthritis Research
Society International
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Presently available therapeutic modalities for osteoarthritis
(OA) are directed at symptoms, with no device or drug
consistently shown to modify structure (joint pathology).
Definitions for the design and conduct of clinical trials have
been developed by the Osteoarthritis Research Society
International (OARSI)1 the World Health OrganizationAddress correspondence to: Roy D. Altman, M.D., NH207G,
Miami VAMC, 1201 NW 16th Street, Miami, FL 33125, U.S.A.
Tel.: +1 305-243-5735; Fax: +1 305-243-5655; E-mail:
raltman@med.miami.edu
395(WHO), the International League of Association for Rheu-
matologists (ILAR),2 the experts involved in Outcome
Measures in Arthritis Clinical Trials (OMERACT),3 and the
European Group for the Respect of Ethics and Excellence
in Sciences (GREES) through an Osteoarthritis Sub-
committee.4 All recommend a clear separation of the evalu-
ation of the symptoms from the evaluation of the structure
(disease) in OA.
In the evaluation of symptoms of OA, several domains
can be considered. Examples include pain, function,
inflammation, range of motion, quality of life, patient’s
global opinion, physician’s global opinion, etc. However,
discussion at OMERACT III focused on three domains,
identified as core variables to be included in all clinical
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BASIC APPROACH
There are several potential approaches to the develop-
ment of response criteria. One utilizes data from clinical
trials with a statistical strategy that defines the criteria. This
approach is limited by the quality of the data, but has the
advantage of being evidence-based. Another approach
relies solely on the judgement of experts. The Delphi
methodology may help focus the process. This approach is
limited because the developed criteria may be statistically
unobtainable, but has the advantage that they probably
represent clinically relevant goals of management. The
OARSI Standing Committee on Clinical Trials elected to
take a third approach, one that takes advantage of the
strengths of both strategies, while minimizing the impact of
their disadvantages.The Standing Committee on Clinical Trials first set out to
clearly define the process for the development of response
criteria. Although the majority of the effort would be by the
committee members, different steps of the project would be
discussed among experts from several fields: rheumatolo-
gists, epidemiologists, biostatisticians, representatives of
the pharmaceutical industry and representatives of health
regulatory agencies [Food and Drug Administration (FDA)
and European Agency for the Evaluation of Medicinal
Products (EMEA)].
It was agreed that the data to be processed in the
analysis would be provided by the pharmaceutical industry,
and that these data would be from clinical trials performed
under their direction by good clinical practice guidelines.
The clinical trial data would be from placebo controlled
clinical trials involving an active agent of a minimum
6 week duration of study. The active agent would not be
identified by name, but only by class of agent. In order to
maintain the anonymity of the agents, the contributors to
this trial are not identified in the text or the acknowledge-
ment. Although not specified in the data collection, all
agents have been approved by either the European or US
health regulatory agencies.DATASET COLLECTION
Datasets and protocols from 37 clinical trials were pro-
vided by the participating pharmaceutical and biotechnol-
ogy companies. To be eligible, the datasets were to include
double-blind, parallel and placebo controlled trials con-
ducted on patients suffering from either hip or knee OA in
which at least one of the following clinical variables was
collected as a primary efficacy variable during the trial: pain
or function (as an assessment of functional disability), or a
global assessment by the patient. Minimal data had to
include these variables at baseline and after treatment.
Studies included in the analysis had to show a benefit
(positive study) from the study medication/agent when
compared to placebo for the primary efficacy variable
(P≥0.05). The study did not include non-pharmacologic
modalities.DEFINITION OF THE OUTCOMES WITHIN EACH DOMAIN
Studies often applied different outcome assessment
instruments in the measurement of each of the domains.
For example, pain may have been measured by the
five-question subscale of the WOMAC, as a part of
the Lequesne Functional Severity Index, or by a single
question. The following outcomes were chosen for
subsequent analyses.Pain
The pain measurement selected for analysis included
the following in rank order: (1) global measure of pain; if not
available, (2) WOMAC pain subscale; if not available, (3)
average of the four questions of Lequesne Functional
Severity Index that focused on pain (i.e. pain at night, pain
in the standing position, pain during walking and pain while
switching from a sitting to a standing position).Function
The functional disability measurement selected for
analysis included the following in rank order: (1) WOMACstudies involving OA, i.e. pain, function and patient’s global
assessment.
Within each of these three domains, several instruments
may be considered, such as a simple visual analog scale
(VAS) or Likert scale. Measurement may also be by a more
complex instrument, such as the Lequesne Functional
Severity Index,5 the Western Ontario McMasters Univer-
sities Osteoarthritis (WOMAC) index,6 the Health Assess-
ment Questionnaire (HAQ) and the Arthritis Impact
Measurement Scales (AIMS).7
While defining a core set of domains to be measured
represents an advance in defining and standardizing the
conduct of OA clinical trials, the analysis and reporting of
results continues to be based on average improvement for
the study population on each of the outcomes measured.
Hence, the average improvement experienced by a group
of treated patients is compared to the average improve-
ment of another group of treated patients (treatment of
which may be placebo). In contrast, for rheumatoid arthritis
there have been at least two sets of multi-variable response
criteria proposed in order to present the results obtained in
clinical trials for an individual.8,9 There are presently no
such criteria available for OA.
Such response criteria in clinical trials offer the following
advantages:
(1) They permit a single statistical analysis. This takes
into account clinically important changes on multiple
variables, without the need for correction for multiple
comparisons, and provides an exact determination for
each individual as to whether or not they have
responded to the study treatment.
(2) They facilitate the categorical analysis of groups of
patients in clinical trials based on definitions of
responders and non-responders.
(3) They allow the comparison of data from different
clinical trials in OA.
Response criteria may also have application in the cal-
culation of sample size for clinical trials,10 assist in phar-
macoeconomic analysis and in data analysis of the
Cochrane Collaborative Project,11 and facilitate calculation
in the number needed to treat approach of data analysis.12
For these reasons, the OARSI Standing Committee on
Clinical Trials elected to develop a set of responder criteria
for the knee and hip. The committee felt that any such
criteria should be research-based to the extent that is
possible.
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questions of Lequesne Functional Severity Index that
focused on functional impairment (i.e. the last four ques-
tions of either the hip or knee Lequesne Functional Severity
Index).
Some datasets contained only the total score of the
Lequesne Functional Severity Index, while others con-
tained both the total score and the response to each of the
11 questions. We examined the correlation of the infor-
mation contained in the 11 questions of the Lequesne
functional severity index, and the four specific questions on
function. This analysis was conducted on available base-
line data from 1748 patients. The following equation was
able to explain >63% of the variance:
Lequesne’s function subscale=
−0.22569+0.43204×(Lequesne total)−
0.00691×(Lequesne total)2
This methodology was implemented in one study of 342
patients.Patient’s global assessment
The patient’s global assessment measurement was
selected for analysis. Because not all data sets contained
this information, we attempted to explain the variable
evaluating ‘patient’s global assessment’ by the information
contained in the variables evaluating the domains ‘pain’
and ‘function’. Analysis of 892 patients’ data, from five
studies where all three domains were available, revealed
that pain and function explained no more than 27% of the
variance of the patient’s global assessment. Hence, studies
without a patient’s global assessment could not be used in
the development of the responder index.RESCALING OF THE OUTCOME MEASURES
Studies often utilized instruments with different scales.
For example, some studies have used a 10 cm VAS or a
Likert scale with a variable number of questions. Other
examples include a 0–8 interval for the pain questions from
the Lequesne functional severity index and the 0–500
interval for the sum of the pain subscale of the WOMAC.
When both were present in the same study, a 100 mm VAS
was used in lieu of a Likert scale. All scales that used
anything other than a 0–100 measurement were rescaled
to a 0–100 interval for the purposes of this study,
henceforth referred to as normalized units or NU.FORMAT OF THE SET OF CRITERIA
The following three formats were considered:
1. The ‘Osteoarthritis Disease Activity Score’.13 This
format involves a composite index using an equation
obtained using multiple regression. The advantage of this
method is that it develops a single number summarizing the
clinical symptoms for each single patient at each visit.
However, its use is usually based on a discriminate analy-
sis comparing high and low disease activity. Such analysis
requires an external judgement, which was not available
in the different datasets. Therefore, this proposition was
rejected.2. The ‘tree’ type format.14 In this format, patients are
partitioned into mutually exclusive categories based on the
outcome measures. The tree selects the most appropriate
variable that can differentiate two populations. It does the
selection in sequential steps, selecting the most appropri-
ate variable at each step. The final tree allows classification
of all patients as responder or nonresponder.
3. The American College of Rheumatology rheumatoid
arthritis, or ‘ACR-RA-set’ format.8 This technique counts
the number of criteria present and if that number exceeds
some pre-specified number the patient is classified as a
responder. This format is easily understood by clinicians
and easily applied in practice. This method does not
consider the severity of disease activity at baseline. For
example, a 50% improvement can be obtained in a patient
with a pain VAS decreasing from 80 to 40, but also for a
patient with a pain VAS decreasing from 6 to 3.
It was elected to take advantage of the latter two formats
with the addition of a minimum response. For example, an
‘X’% improvement in pain, function or patient’s global
assessment from baseline would have to be accompanied
by a minimum improvement of ‘Y’ NU (rescaled variable in
normalized units, see above). Intent-to-treat analysis (ITT)
with last observation carried forward (LOCF) was used for
all studies.STUDIED POPULATIONS
Data were available to allow the separation of the
following subsets: (1) patients with knee OA on an oral
non-steroidal anti-inflammatory drug (NSAID); (2) patients
with knee OA on a non-NSAID anti-OA oral drug; (3) hip OA
on an oral NSAID; (4) knee OA receiving an intra-articular
anti-OA specific non-steroidal agent. Insufficient data were
available to examine hip OA on a non-NSAID anti-OA drug,
intra-articular depocorticosteroids and intra-articular agents
for hip OA.PROPOSED SET OF CRITERIA
Eighteen scenarios defining responders were examined.
To illustrate a very conservative scenario, a patient is
considered as a responder if he/she fulfills the following: ‘an
improvement in pain AND in function AND in global assess-
ment’. For each proposed scenario, a statistical analysis
based on the response criteria capacity to discriminate
active and placebo groups was used to evaluate the
performance of different cut-off points (in both the percent-
age of change and the absolute change) for each single
variable included in this scenario. However, before this
analysis, the members of the Standing Committee on
Clinical Trials proposed a range for each variable that
should be explored together with a minimum interval
between the different values that should be evaluated (i.e.
a minimum interval of 5% or 5 NU). Different definitions of
response criteria corresponding to different combinations of
cut-offs were evaluated. The definition retained (with fixed
cut-offs) was the one which maximizes the difference
between the percentage of responders in the active group
(‘sensitivity’) and the percentage of responders in the
placebo group (‘1-specificity’).
ResultsPATIENTS AND STUDY COURSE
The number of studies examined and the screening of
those studies are illustrated in Fig. 1. The majority of the
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of the domains to be examined, mostly the patient’s global
assessment. Figure 1 also outlines the number of patients
involved in the screening process and the numbers derived
for each of the subsets to be examined. Although
requested, there were no trials available to examine anal-
gesics (narcotic or non-narcotic) in OA. The screening
reduced the number of trials from 37 to 14 and the number
of patients in those trials from 5512 to 1886. The majority of
information was on NSAIDs for knee and hip.
The characteristics of the study populations are summa-
rized in Table I. The placebo and active drug groups were
similar in age, sex and body mass index. The populations
were relatively overweight as reflected by a high body mass
index. In general there were more patients receiving active
drug than placebo as several trials had more than one armreceiving active drug. The trials examined were relatively
recent as reflected by the common use of the WOMAC.
The baseline values in NU and the percent change
during the study of the three selected domains are sum-
marized for each of the study subsets in Table II. These
data confirm that most of the patients were quite sympto-
matic at entry since the mean values of pain, functional
impairment and patient’s global assessment were all over
40 NU. Moreover, the values obtained in the variable
‘patient’s global assessment’ were over 60 NU, higher than
the values for ‘pain’ and/or ‘function’. Consistent with the
requirement that only positive studies be included, the
changes from baseline in the ‘active’ group were of greater
magnitude than the ‘placebo’ group for all domains. It was
not possible to determine worsening in the studies of knee
intra-articular specific anti-OA drug, as the the change in
‘function’ and ‘patient’s global assessment’ were collected
at the end of the study by asking the patients about the
level of his/her ‘improvement’.Fig. 1. Flow diagram for numbers of studies and patients.Table I
Characteristics of the patients included for the development of the response criteria
Characteristics Selected population
Placebo Active drug
Age (years) (mean±S.D.) 63±10 63±10
Sex (% women) 72 72
Body mass index (kg/m2) (mean±S.D.) 31± 7 30± 7
Localization
Hip (number) 197 480
Knee (number) 362 847
Route of administration
Oral (number) 460 1232
Intra-articular (number) 99 95
Class of the active drug
NSAIDs (number) 372 977
Specific anti-OA drug (number) 187 350
Domains and outcome assessment instrument
Pain
Global VAS pain (number, 3 studies) 179 563
WOMAC pain subscale (number, 8 studies) 281 658
4 questions of the algo-functional index (number, 3 studies) 99 95
Function
WOMAC pain subscale: (number, 8 studies) 281 658
4 questions of the algo-functional index (number, 3 studies) 179 574
Patient’s global assessment
Global VAS (number) 228 707
Global Likert scale (number) 232 525DEVELOPMENT OF SETS OF CRITERIA
There were 18 different response criteria evaluated.
Each was evaluated for NSAID hip, NSAID knee, anti-OA
drug hip, anti-OA drug knee and knee intra-articular specific
anti-OA drug. Numerous cut-offs on percent change and
change in NU were reviewed on each of the 18 response
criteria for each of the three domains. Each evaluation
included sensitivity and specificity. Two sets of response
criteria were statistically superior and felt to be clinically
relevant (Figs 2 and 3).
The first scenario (proposition A) (Fig. 2) emphasizes the
domain ‘pain’. A ‘high’ improvement in pain was sufficient to
define a responder. However, using this set of criteria, a
patient can be also considered as a responder if an
improvement of ‘moderate’ magnitude is observed in two of
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Baseline values and changes after therapy (percentage±standard deviation: standardized units, 0–100 scale) in the three selected domains
(pain, function, patient’s global assessment) with regard to osteoarthritis localization and category of the active drug
Domains Hip osteoarthritis
NSAID study therapy
Knee osteoarthritis
NSAID study therapy
Knee osteoarthritis
specific therapy
Knee osteoarthritis
intra-articular
specific therapy
Placebo
N=197
Active drug
N=480
Placebo
N=175
Active drug
N=197
Placebo
N=88
Active drug
N=255
Placebo
N=99
Active drug
N=95
Pain
Baseline value 64±19 62±21 58±22 59±22 58±12 59±12 56±20 52±19
Changes during the study −14±53 −34±62 −4±73 −23±90 −34±55 −46±43 −24±40 −61±28
Functional impairment
Baseline value 58±17 58±16 56±20 56±21 41± 7 41± 8 NA NA
Changes during the study −2±38 −21± 4 −7±64 −23±54 −28±45 −34±41 −42±16 −47±10
Patient’s global assessment
Baseline value 72±16 72±17 70±18 72±17 61±15 61±16 NA NA
Changes during the study −22±59 −45±40 −19±40 −41±39 −30± 5 −41±43 −39±32 −79±26Fig. 2. OARSI Responder Criteria—Proposition A. Decision tree is
utilized for each patient. If there is a ‘high’ improvement in pain, the
person is considered a responder. If there is not a ‘high’ response
to pain, they must have a ‘moderate’ response to two or three of
the domains to be labeled a responder.Fig. 3. OARSI Responder Criteria—Proposition B. Decision tree is
utilized for each patient. If there is a ‘high’ improvement in pain or
function, the person is considered a responder. If there is not a
‘high’ response to pain, they must have a ‘moderate’ response to
two or three of the domains to be labeled a responder.the three domains, i.e. pain, function and patient’s global
assessment.
The second scenario (proposition B) (Fig. 3) is similar to
the first and with nearly identical statistical results. This
scenario applies equal importance to ‘pain’ and ‘function’,
requiring a ‘high’ response of one OR the other. Alterna-
tively, a ‘moderate’ magnitude of response could be
present in two of the three domains.
Optimal cut-offs for the different subgroups were pro-
posed based on statistical analysis (Tables III and IV). The
proposed cut-offs are different for proposition A and propo-
sition B and are different for each intervention and joint.
Attempts to develop a single OA response criteria that
would include the different subgroups led to important loss
of separation of active and placebo groups; the loss was
only 1–2% in sensitivity, but nearly 15% in specificity.
Considering the first step of the decision tree for both
sets of response criteria, the different statistical analyses in
the different subgroups concluded that an improvement of
at least 40% was required (ranging from 40 to 60%)
together with an absolute improvement of at least 20 NU
ranging from 20 to 30. Considering the second step, an
improvement of lower magnitude was required—a relativeimprovement ranging from 15 to 35% and an absolute
improvement ranging from 10 to 20 NU. The results con-
cerning the performance of the sets of response criteria in
terms of sensitivity (i.e. percentage of responders in the
group of patients who received the active drug) and
1-specificity (i.e. percentage of responders in the group of
patients who received the placebo) are summarized in
Tables V and VI.
Figure 4 exemplifies how the tables can be used and
corresponds to the second row of Table III: responder
criteria for knee OA using an oral NSAID. A major criterion
would be a 45% reduction in pain with a minimum decrease
of 20 NU (i.e. 20 mm on a 100 mm VAS). If that were not
achieved, the minor criterion for a responder would be
someone achieving a change in at least two of the following
three domains: a reduction of pain of at least 15% (mini-
mum reduction of 10 NU); improvement in function of at
least 30% (minimum improvement of 15 NU); and/or an
improvement in patient’s global assessment of at least 35%
(minimum improvement of at least 10 NU).
In the NSAIDs trials (hip or knee), the percentage of
responders is close to what might be expected from prior
trials in rheumatic diseases (i.e. 50–60% in the active
400 M. Dougados et al.: Response criteria for clinical trials on osteoarthritisgroups vs 20–30% in the placebo group). These figures are
different in both the ‘knee systemic specific drug’ and the
‘knee intra-articular specific drug’ in which the percentage
of placebo responders was higher (respectively, 51 and
47% in proposition A and 50 and 47% in proposition B).Table III
Optimal cut-offs to be applied for the OARSI-Responder Criteria—proposition A (see Fig. 2)
Subgroup High improvement Moderate improvement in
in pain Pain Function Global assessment
Relative
change*
Absolute
change**
Relative
change
Absolute
change
Relative
change
Absolute
change
Relative
change
Absolute
change
Hip NSAIDs 60 20 35 20 20 10 30 10
Knee oral NSAIDs 45 20 15 10 30 15 35 10
Knee oral specific drug 55 30 35 10 15 20 15 15
The three above groups together 55 30 35 15 15 20 15 15
Knee intra-articular specific drug 40 30 35 15 35 10 30 10
*Relative change: percentage of change during the study (final minus baseline over baseline×100).
**Absolute change: absolute change during the study (final minus baseline on a 0–100 interval scale).Table IV
Optimal cut-offs to be applied for the OARSI-Responder Criteria—proposition B (see Fig. 3)
Subgroup High improvement in Moderate improvement
Pain Function Pain Function Global assessment
Relative
change*
Absolute
change**
Relative
change
Absolute
change
Relative
change
Absolute
change
Relative
change
Absolute
change
Relative
change
Absolute
change
Hip NSAIDs 50 30 50 20 25 15 20 10 20 10
Knee oral NSAIDs 50 20 60 20 30 15 20 20 25 10
Knee oral specific drug 55 30 50 20 30 20 20 20 20 15
The three above groups together 55 30 50 20 30 15 20 20 20 15
Knee intra-articular specific drug 50 30 60 20 20 20 30 10 30 10
*Relative change: percentage of change during the study (final minus baseline over baseline×100).
**Absolute change: absolute change during the study (final minus baseline on a 0–100 interval scale).Table V
Percent of study patients meeting OARSI responder criteria—proposition A
Subgroup
High improvement
in pain
Moderate improvement
in 2 of the 3:
pain, function,
global assessment Total
Percentage responders Percentage responders Percentage responders
Active* Placebo** Active Placebo Active Placebo
Hip NSAIDs 35% 18% 27% 14% 62% 33%
Knee oral NSAIDs 39% 19% 13% 8% 52% 27%
Knee oral specific drug 49% 39% 13% 12% 62% 51%
Knee intra-articular specific drug 44% 18% 48% 29% 92% 47%
*Active: sensitivity=% responders on active drug.
**Placebo: 1—specificity=% responders on placebo.Discussion
This study combined the efforts of academic researchers,
biostatisticians, representatives of the pharmaceutical
industry and representatives of health agencies to develop
responder criteria for clinical trials of OA of hip and knee.The data led the Standing Committee on Clinical Trials to
propose two sets of responder criteria, with variation in the
specific recommendations for hip and knee and for different
therapeutic approaches.
The authors are unaware of any previously proposed
responder criteria for OA. The proposed responder criteria
include the core set of outcome measures for OA clinical
trials developed at OMERACT III: pain, function and
patient’s global assessment. These outcome measures
have also been recommended by the OARSI and various
health regulatory agencies.
There are limitations to this study. Because of variations
in study design a majority of the screened studies, and
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Percent of study patients meeting OARSI responder criteria—proposition B
Subgroup
High improvement
in pain
Moderate improvement
in 2 of the 3:
pain, function,
global assessment Total
Percentage responders Percentage responders Percentage responders
Active* Placebo** Active Placebo Active Placebo
Hip NSAIDs 39% 27% 24% 12% 69% 39%
Knee oral NSAIDs 39% 19% 12% 7% 51% 26%
Knee oral specific drug 52% 40% 9% 10% 61% 50%
Knee intra-articular specific drug 51% 29% 39% 18% 91% 47%
*Active: sensitivity=% responders on active drug.
**Placebo: 1—specificity=% responders on placebo.Fig. 4. OARSI Responder Criteria—example of proposition A for
knee oral NSAID subgroup. This decision tree exemplifies the use
of the algorithm for a patient in a clinical trial that is testing an
non-steroidal anti-inflammatory drug for osteoarthritis of the knee.
In this instance a ‘high’ improvement in pain equates to a 45%
reduction in pain that is also a minimal change of 20 NU or
normalized units. Twenty normalized units equates to a minimal
change of 20 mm on a 100 mm scale. If the patient achieves this
reduction in pain, they are considered a responder. If they do not,
to be considered a responder the patient must achieve a positive
result in at least two of the three domains: i.e. pain would need a
reduction of 15% with a minimal change of 10 mm on a 100 mm
scale, function would require a 30% improvement for a minimal
15 mm on a 100 mm scale and the patient’s global assessment
would need a 35% improvement with a minimal 10 mm change on
a 100 mm scale. This algorithm labeled 52% of the 197 patients on
an NSAID as responders and 73% of the 175 patients on placebo
as non-responders.hence a majority of the patients, had to be excluded from
the analysis. Even in studies included in the analysis
scores had to be generated from existing data that had
been collected in different formats. The above studies were
of variable duration; the influence of time of study on the
response criteria was not addressed.
Different information gathering instruments were used.
The outcomes from these different instruments may be
similar but their responsiveness to change may be different.
There is a question as to whether subscales can be
extracted from instruments that were not developed around
a subscale structure. There are also limitations imposed bymodeling in order to input values of real data. Few, if any of
the studies asked for the patient’s global assessment in the
same way.
The different instruments and even some of the same
instruments used different scales, requiring a rescaling to a
common 0–100 scale in order to normalize values. It is
recommended that future studies use a 0–100 interval. This
would facilitate analysis and provide uniform and under-
standable communication. The 0–100 interval would allow
the use of the proposed responder criteria, emphasizing
minimum change in NU.
The proposed responder criteria utilize a format that
requires an absolute change. The technique also includes
a second layer in a simple ‘tree’ format giving heirarchal
application of criteria. In order to address severity of
disease at baseline, a minimum level of improvement was
also required. Whatever the rating scale used, the appli-
cation of the proposed set of response criteria is feasible
(for example, a required absolute improvement of 10% in
the variable means an improvement of at least one grade
for a 0–4 Likert scale, 2.4 points for a 0–24 scale, etc.).
It should be pointed out that the use of these responder
criteria will require a protocol to set minimum entry criteria,
since attainment of response by these criteria must remain
an achievable target for all participants. Individuals with
baseline values less than the minimum required absolute
change can never be designated as responders, even if
they are rendered symptom free. Hence, trials using these
responder criteria should not be used in trials examining
milder symptomatic patients. Moreover, since it is not
anticipated that many patients would become symptom
free, the entry criteria need to be set somewhere above the
minimum required to fulfill these responder criteria.
The choice of the different cut-offs was based on statisti-
cal analysis for optimization of the discriminant capacity.
The results obtained are close to those expected in the field
of OA, i.e. a 20–30% placebo response and a 20–30%
treatment effect.14,15 It is of note that the placebo response
in intra-articular studies may be as high as 50%.
The placebo response for hip and knee with an NSAID
varied from those obtained in two other subgroups. In the
subgroup ‘knee-oral specific OA drug’, the placebo effect
was greater than in the other subgroups. This difference in
the placebo effect might be explained by the concomitant
therapy. In NSAIDs trials, acetaminophen was the most
commonly permitted rescue medication. In the ‘specific
osteoarthritic drug’ trials, both acetaminophen and NSAIDs
intake was commonly permitted. Considering the subgroup
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the treatment effect were of greater magnitude than in the
other subgroups. The higher placebo effect may be explain-
able by knee aspiration at the time of the procedure and
by a higher placebo effect associated with the route of
administration.17,19
The higher treatment effect for intra-articular therapy is
more difficult to interpret. It is possible that treatment with
an intra-articular specific OA drug is of greater magnitude
than any drug given orally. However, in the trials reviewed
in this effort, the questions concerning the level of pain,
functional disability and global assessment were not
related to the absolute condition of the patient at the end of
the study, but to the relative improvement of the patient;
hence, it was not possible to detect worsening during these
trials. The authors feel that the sensitivity and specificity
obtained in this subgroup should be interpreted with
caution.
Specific cut-offs are proposed for the responder criteria.
Additional cut-offs were examined, such as a uniform
cut-off for all subsets. Unfortunately, these alternative cut-
offs showed an important loss of sensitivity and sensitivity.
Because of the lack of available databases, some OA
conditions were not evaluated, such as hip oral-specific OA
drugs, analgesics, and hand OA.
Two sets of responder criteria were developed in this
initiative. The performances of the two sets of criteria in the
different evaluated subgroups are similar. One could con-
sider that proposition A is more simple and therefore should
be retained. However, the members of the committee,
together with other participants in this initiative consider
that in some studies changes in functional disability are at
least as important as the changes in pain. Hence, proposi-
tion B is also included. Finally, these sets of responder
criteria should be considered as preliminary. Further
studies are needed in order to validate these proposals in
other sets of patients and with different drugs.Acknowledgments
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